ClinicalTrials.gg
CompletedNCT07941960Updated Nov 17, 2026

Efficacy of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Bupivacaine

An interventional study of Dexamethasone and Dexmedetomidine in Supraclavicular Brachial Plexus Block, sponsored by Muhammad Aamir Latif. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2025, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Various adjuvants, including dexamethasone and dexmedetomidine, have been explored to improve block quality and prolong postoperative analgesia. However, local evidence comparing their efficacy is limited. Therefore, this study aims to compare bupivacaine plus dexamethasone versus bupivacaine plus dexmedetomidine in terms of onset and duration of sensory and motor blockade and postoperative analgesia.

Read the detailed description

Although local anesthetics like bupivacaine, known for their long duration of action, are frequently employed for Supraclavicular Brachial Plexus Block (SCBP), the limited duration of postoperative analgesia remains a challenge. To address this, various adjuvants, such as opioids, midazolam, magnesium sulfate, neostigmine, dexamethasone, and dexmedetomidine, have been explored to enhance block quality, prolong analgesia, and reduce side effects. Dexmedetomidine, a selective α2-adrenoceptor agonist, has demonstrated efficacy in extending sensory and motor blockade when combined with local anesthetics. Similarly, dexamethasone, a potent glucocorticoid with anti-inflammatory and analgesic properties, has shown promising results in prolonging block duration by inhibiting nociceptive fiber transmission and neuronal discharge. However, the comparative benefits of these adjuvants warrant further evaluation, as identifying the more effective option may help optimize block characteristics, improve postoperative pain control, reduce analgesic requirements, and enhance patient satisfaction.

02

Conditions studied

  • Supraclavicular Brachial Plexus Block
03

In context

Lead sponsor

Muhammad Aamir Latif is the lead sponsor of 59 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either gender
  • Aged 18-75 years
  • Scheduled for elective upper limb surgeries (including orthopedic, plastic, and general surgical procedures)
  • (BMI) of less than 36 kg/m²
  • (ASA) grades I and II

Exclusion criteria

Exclusion Criteria:

  • Local infection at the puncture site
  • Any neurological deficit in the upper limb
  • History of hematological disorders (such as coagulation abnormalities, severe renal impairment, hepatic dysfunction, or known pain syndromes)
  • Known allergy to the study drug or its additives
  • Pregnant or lactating women
  • The use of systemic for two weeks or longer
  • History of substance abuse or drug addiction
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Dexamethasone-Group

    Patients were administered 20 mL of 0.5% bupivacaine with 4 mg (1 mL) of dexamethasone.

    Drug: Dexamethasone

  • Experimental
    Dexmedetomidine-Group

    Patients were given 20 mL of 0.5% bupivacaine with 1 µg/kg (2 mL) of dexmedetomidine.

    Drug: Dexmedetomidine

Interventions

  • Patients were administered 20 mL of 0.5% bupivacaine with 4 mg (1 mL) of dexamethasone.

  • Patients were given 20 ml of 0.5% bupivacaine with 1 µg/kg (2 ml) of dexmedetomidine.

06

What researchers measure

Primary outcomes

  1. Onset and duration of sensory blockade

    Onset of sensory blockade is defined as the time elapsed from anesthetic injection to complete loss of pinprick sensation (score 2). Duration is defined as the interval between achieving complete sensory blockade (score 2) and full return of sensation (score 0) in the blocked dermatomes. Both are measured in minutes.

    Time frame: Perioperative period, i.e., up to 24 hours after anesthetic administration.

  2. Onset and duration of motor blockade

    Onset of motor blockade is defined as the time elapsed from anesthetic injection to complete loss of muscle power (score 2). Duration is defined as the interval between achieving complete motor blockade (score 2) and full recovery of hand and forearm muscle function (score 0), measured in minutes.

    Time frame: Perioperative period, i.e., up to 24 hours after anesthetic administration.

  3. Duration of postoperative analgesia

    Defined as the time elapsed from anesthetic administration to the first request for rescue analgesia, indicated by a Visual Analogue Scale (VAS) score of 4, measured in minutes.

    Time frame: Postoperative period, i.e., up to 24 hours after anesthetic administration.

07

Study locations

1 site
  • Islamabad Hospital/Pakistan Institute of Medical Sciences, Islamabad
    Islamabad, Punjab Province 44000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 17, 2026
StartActual
Oct 1, 2025
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941960
Lead sponsor
Muhammad Aamir Latif
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Oct 1, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Nov 17, 2026

Study contacts

Shumaim Bint-e-Akram
principal investigator · Islamabad Hospital/Pakistan Institute of Medical Sciences, Islamabad.
Imran Sikandar, FCPS
study director · Islamabad Hospital/Pakistan Institute of Medical Sciences, Islamabad.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Dexmedetomidine

Start the discussion